Ophthalmology and Therapy最新文献

筛选
英文 中文
Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters. 基于各种理化参数的欧洲 37 种泪液替代品概览。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-03 DOI: 10.1007/s40123-024-01023-9
Adrien Paschier, Aurélie Manuelli, Laure Chauchat, Morgane Legall, Hayette Rebika, Marwan Sahyoun, Camille Guerin
{"title":"Overview of 37 Tear Substitutes in Europe Based on Various Physicochemical Parameters.","authors":"Adrien Paschier, Aurélie Manuelli, Laure Chauchat, Morgane Legall, Hayette Rebika, Marwan Sahyoun, Camille Guerin","doi":"10.1007/s40123-024-01023-9","DOIUrl":"10.1007/s40123-024-01023-9","url":null,"abstract":"<p><strong>Introduction: </strong>Dry eye disease (DED) is one of the most prevalent eye conditions worldwide, with artificial tears serving as a primary treatment option. Despite their wide availability on the European market, there is a lack of established classifications based on their physicochemical properties. The aim of our study was therefore (i) to develop an analytical method that measures the concentration and the molecular weight (MW) of the hyaluronic acid (HA) in commercialized products, and (ii) to propose an overview based on their various physicochemical parameters.</p><p><strong>Methods: </strong>The intrinsic viscosity and MW of the HA, as well as osmolarity, pH, rheological profile, and viscosity, were measured or determined. A specific method was developed to measure the average intrinsic viscosity and HA content using a liquid size-exclusion chromatography system. The MW was determined using the Mark-Houwink equation.</p><p><strong>Results: </strong>Thirty-seven products commercialized in Europe were analyzed, with 21 of them containing HA. The HA MW was lowest (300 kDa) for Thealose<sup>®</sup>, Thealoz Duo<sup>®</sup> Gel, and Hyabak<sup>®</sup>, and highest (1300 kDa) for Vismed<sup>®</sup> Multi, Vismed<sup>®</sup> Gel, and Neovis<sup>®</sup> Gel. The pH values varied between 5.94 for Treovis<sup>®</sup> and 8.06 for Systane<sup>®</sup> Ultra. Osmolarity ranged between 148 mOsm/L and 325 mOsm/L for Neovis<sup>®</sup> and Treovis<sup>®</sup>, respectively. Viscosity was highly variable, ranging from 0.38 mPas·s for Hylolipid<sup>®</sup> to 337.47 mPas·s for Thealoz<sup>®</sup> Duo Gel. Finally, rheological profile analysis revealed different shear-thinning behaviors.</p><p><strong>Conclusion: </strong>While the perfect eye drop does not exist, a multitude of options are available to choose from. This study improves our understanding of the major tear substitutes available on the European market based on several physicochemical properties. A better understanding and awareness of these parameters is crucial in order to offer the best treatment for patients with DED.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2799-2812"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-Term Impacts of Intense Pulsed Light Therapy on Ocular Surface Health and Tear Film Dynamics in Patients with Dry Eye Disease: Detailed Analysis and Observations Over a 1-Year Follow-Up Period. 强脉冲光疗法对干眼症患者眼表健康和泪膜动力学的长期影响:一年随访期的详细分析和观察。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-16 DOI: 10.1007/s40123-024-01017-7
Cristina-Patricia Pac, Mihnea Munteanu, José-María Sánchez-González, Carlos Rocha-de-Lossada, Nadina Mercea, Francis Ferrari, Horia T Stanca, Dan Andrei Radu Cosnita, Mihaela Ionica, Ovidiu Boruga, Ciprian Danielescu, Alexandru Blidisel
{"title":"Long-Term Impacts of Intense Pulsed Light Therapy on Ocular Surface Health and Tear Film Dynamics in Patients with Dry Eye Disease: Detailed Analysis and Observations Over a 1-Year Follow-Up Period.","authors":"Cristina-Patricia Pac, Mihnea Munteanu, José-María Sánchez-González, Carlos Rocha-de-Lossada, Nadina Mercea, Francis Ferrari, Horia T Stanca, Dan Andrei Radu Cosnita, Mihaela Ionica, Ovidiu Boruga, Ciprian Danielescu, Alexandru Blidisel","doi":"10.1007/s40123-024-01017-7","DOIUrl":"10.1007/s40123-024-01017-7","url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate the long-term effects of intense pulsed light (IPL) therapy on patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD).</p><p><strong>Methods: </strong>A retrospective case series was performed with 110 participants undergoing IPL therapy. Assessments included the eye fitness test (EFT) to gauge subjective symptoms, along with objective measures using the Tearcheck<sup>®</sup> device (ESW Vision, Houdan, France) noninvasive first breakup time (NIFBUT), noninvasive average breakup time (NIABUT), central tear meniscus height (CTMH), thinnest tear meniscus height (TTMH), and ocular surface inflammatory risk evaluation (OSIE) assessed using the SCHWIND SIRIUS device (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany).</p><p><strong>Results: </strong>This study documented significant improvements in subjective and objective symptoms associated with DED and MGD. Subjective symptoms measured by the EFT showed an average increase of 9.74 points (range -10 to 28, standard deviation [SD] ± 7.54), indicating reduced symptoms. Objective measures of tear film stability, represented by NIABUT, increased by an average of 4.04 s (range -15.00 to 14.40, SD ± 4.91). Tear film stability evaluation (TFSE) scores decreased by 229.12 points on average (range -1775 to 528, SD ± 384.94), suggesting enhanced tear film stability. OSIE type 1 showed a reduction in inflammation, with a percentage decrease of 4.98% (range -45 to 5, SD ± 7.33). Additionally, OSIE capture time decreased by 3.25 s on average (range -27 to 22, SD ± 10.35), further indicating an improvement in ocular surface health.</p><p><strong>Conclusion: </strong>IPL therapy was shown to be a promising, noninvasive approach for improving quality of life in patients with DED by effectively managing symptoms and stabilizing tear film. The findings support the use of IPL as a sustainable treatment modality for DED associated with MGD.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2715-2730"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Excisional Goniotomy with the Kahook Dual Blade: 6-Year Results. 使用 Kahook 双刀进行割除性神经节切除术的临床效果:6 年结果。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-16 DOI: 10.1007/s40123-024-01016-8
Pranav Vasu, Yazan Abubaker, Nithya Boopathiraj, Isabella V Wagner, P Connor Lentz, Emily Dorairaj, Aya Shokair, Ibrahim Qozat, Darby D Miller, Syril Dorairaj
{"title":"Clinical Outcomes of Excisional Goniotomy with the Kahook Dual Blade: 6-Year Results.","authors":"Pranav Vasu, Yazan Abubaker, Nithya Boopathiraj, Isabella V Wagner, P Connor Lentz, Emily Dorairaj, Aya Shokair, Ibrahim Qozat, Darby D Miller, Syril Dorairaj","doi":"10.1007/s40123-024-01016-8","DOIUrl":"10.1007/s40123-024-01016-8","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to evaluate the long-term clinical outcomes of excisional goniotomy with the Kahook Dual Blade (KDB) in the management of various types of glaucoma.</p><p><strong>Methods: </strong>This was a retrospective, noncomparative chart review of 90 eyes of 53 patients with glaucoma that underwent standalone KDB goniotomy (KDB-alone group) or KDB goniotomy with concomitant phacoemulsification (KDB-phaco group) between October 2015 and October 2017. Surgical success was defined as an intraocular pressure (IOP) reduction by ≥ 20% at the last follow-up with no surgical reinterventions required and a final IOP ≥ 4 mmHg and ≤ 21 mmHg. We also report on changes from baseline in IOP, number of glaucoma medications, best-corrected visual acuity (BCVA), and visual field parameters, for up to 72 months.</p><p><strong>Results: </strong>At 72 months, mean (standard deviation [SD]) IOP was reduced from 17.5 (5.7) to 13.6 (3.0) mmHg (P < 0.0001) in the KDB-phaco group and from 23.3 (5.9) to 15.1 (6.2) mmHg (P = 0.0593) in the KDB-alone group. The mean (SD) number of glaucoma medications was reduced from 1.3 (1.0) to 0.8 (0.9) (P < 0.0001) in the KDB-phaco group and from 1.2 (1.0) to 0.7 (0.8) (P = 0.3409) in the KDB-alone group. During the 72-month follow-up, surgical success was achieved in 24 of the 52 available eyes (46.2%). Four eyes underwent a glaucoma surgical reintervention by 72 months.</p><p><strong>Conclusions: </strong>Excisional goniotomy with the KDB effectively lowered the IOP (by an average of 28.0% from baseline) and maintained or further reduced glaucoma medication burdens (by an average of 30.8% from baseline) under an excellent safety profile, independent of phacoemulsification status. The procedure exhibited favorable success for up to 6 years, providing valuable insights into its long-term efficacy as a glaucoma treatment.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2731-2744"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab. 大剂量布卢珠单抗治疗对标准剂量布卢珠单抗耐药的难治性新生血管性老年性黄斑变性。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-30 DOI: 10.1007/s40123-024-01022-w
Jinsoo Kim, Min Seon Park, Bum-Joo Cho, Soonil Kwon
{"title":"High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab.","authors":"Jinsoo Kim, Min Seon Park, Bum-Joo Cho, Soonil Kwon","doi":"10.1007/s40123-024-01022-w","DOIUrl":"10.1007/s40123-024-01022-w","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate the efficacy and safety of escalating the dosage of intravitreal brolucizumab in patients with refractory neovascular age-related macular degeneration (AMD).</p><p><strong>Methods: </strong>This retrospective study included 17 eyes of 17 patients with refractory AMD treated with high-dose brolucizumab (12 mg/0.1 ml) for over 12 months. Patients initially received at least one anti-vascular endothelial growth factor (anti-VEGF) agent and were switched to standard-dose brolucizumab (6 mg/0.05 ml). Those who showed a suboptimal response to standard-dose treatment had their dosage of brolucizumab escalated.</p><p><strong>Results: </strong>Visual acuity was maintained from 68.3 ± 3.4 letters to 70.7 ± 3.2 letters after 12 months of high-dose treatment (P = 0.128). Central subfield thickness was 343.7 ± 17.0 μm before high-dose treatment and 316.7 ± 18.5 μm at 12 months (P = 0.083). The proportions of patients with subretinal fluid and serous pigment epithelial detachment significantly decreased from 82.4% to 41.2% and from 52.9% to 17.6%, respectively, after high-dose treatment (P = 0.039 and P = 0.031, respectively). The treatment interval extended from 7.2 ± 2.4 weeks to 10.2 ± 2.2 weeks after switching to standard-dose brolucizumab (P < 0.001) and was maintained at 13.5 ± 2.8 weeks after increasing the dose (P = 0.154). No severe ocular adverse events were observed.</p><p><strong>Conclusions: </strong>High-dose brolucizumab was effective in patients who did not respond to standard-dose brolucizumab after switching from previous anti-VEGF agents. Increasing the dosage could offer sustained disease control and reduce the treatment burden for patients with refractory AMD.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2789-2797"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142110495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema. 资源受限系统中的经济评估:湿性老年性黄斑变性和糖尿病性黄斑水肿的个体水平模拟模型。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-06 DOI: 10.1007/s40123-024-00999-8
Tara Li, Vladislav Berdunov, Robin Hamilton, Yaneth Gil Rojas, Christian Bührer, Oliver Cox, Roelien Postema, Marloes Bagijn
{"title":"Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema.","authors":"Tara Li, Vladislav Berdunov, Robin Hamilton, Yaneth Gil Rojas, Christian Bührer, Oliver Cox, Roelien Postema, Marloes Bagijn","doi":"10.1007/s40123-024-00999-8","DOIUrl":"10.1007/s40123-024-00999-8","url":null,"abstract":"<p><strong>Introduction: </strong>Cost-effectiveness analyses typically ignore healthcare system resource constraints. Ophthalmology is affected by resource constraints because of increasing disease prevalence and the use of resource-intensive treatments. This study evaluated the impact of resource constraints on the cost-effectiveness of faricimab 6 mg, compared with aflibercept 2 mg and ranibizumab biosimilar 0.5 mg, for treating wet age-related macular degeneration (wAMD) or diabetic macular oedema (DMO) over a 5-year horizon.</p><p><strong>Methods: </strong>A microsimulation model estimated the impact of resource constraints on patients visits, delays, costs and quality-adjusted life-year (QALY) losses due to treatment delays at a typical UK National Health Service eye hospital treating 1500 patients with wAMD and 500 patients with DMO. Patient characteristics, treatment regimens and treatment intervals were informed using published literature and expert opinion. Resource constraint was represented by limiting the number of available intravitreal injection appointments per week, with growing demand caused by rising disease prevalence. The model compared outcomes across three scenarios; each scenario involved treating all patients with one of the three treatments.</p><p><strong>Results: </strong>Over 5 years, in a resource-constrained hospital, compared with aflibercept, faricimab use resulted in the avoidance of 12,596 delays, saved GBP/£15,108,609 in cost and avoided the loss of 60.06 QALYs. Compared with ranibizumab biosimilar, faricimab use resulted in the avoidance of 18,910 delays, incurred £2,069,088 extra cost and avoided the loss of 105.70 QALYs, resulting in an incremental cost-effectiveness ratio of £19,574/QALY.</p><p><strong>Conclusions: </strong>Accounting for resource constraints in health economic evaluation is crucial. Emerging therapies that are more durable and require less frequent clinic visits can reduce treatment delays, leading to improved QALY outcomes and reduced burden on healthcare systems. Faricimab reduced the number of delayed injections, leading to improved QALY outcomes for patients in a healthcare system with resource constraints. Faricimab is cost-saving when compared with aflibercept and cost-effective when compared with ranibizumab biosimilar.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2577-2597"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment. 观察性临床研究:评估含黄原胶和低浓度磷酸地索奈德的眼科溶液在干眼症治疗中的应用。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-07-26 DOI: 10.1007/s40123-024-01003-z
Pasquale Aragona, Giuseppe Giannaccare, Edoardo Dammino, Fabiana D'Esposito, Paola Genovese, Elisa Imelde Postorino, Claudine Civiale, Maria Grazia Mazzone, Caterina Gagliano
{"title":"Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment.","authors":"Pasquale Aragona, Giuseppe Giannaccare, Edoardo Dammino, Fabiana D'Esposito, Paola Genovese, Elisa Imelde Postorino, Claudine Civiale, Maria Grazia Mazzone, Caterina Gagliano","doi":"10.1007/s40123-024-01003-z","DOIUrl":"10.1007/s40123-024-01003-z","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with dry eye disease (DED) complain of a multitude of symptoms that affect their visual function and quality of life (QoL). This clinical investigation assessed the performance, tolerance, and safety of a novel preservative-free ophthalmic solution containing xanthan gum 0.2% and desonide sodium phosphate 0.025%.</p><p><strong>Methods: </strong>This was an observational, prospective, multicentric, and post-market clinical investigation to assess the effect of three times a day instillation of the study formulation in patients suffering from DED. The primary objective was to achieve a 50% reduction in conjunctival hyperemia index as assessed with the OCULUS Keratograph after 1 month of treatment compared to baseline values. The secondary objectives included patient-reported outcomes, clinical performance, and safety.</p><p><strong>Results: </strong>Thirty patients were enrolled (21 women, 9 men) with a mean age of 61.10 ± 14.53 years. The instillation of the study formulation was associated with a significant reduction in redness scores after 1 month of treatment compared to baseline (mean - 0.51 ± 0.51; p ≤ 0.0001). Although the primary endpoint was not completely met, a 50% reduction in the conjunctival hyperemia index was achieved in 23% of the participants, and 77% showed a reduction of 26% of the same index. In addition, the ophthalmic solution significantly increased tear film break-up time, and a significant reduction of corneal and conjunctival staining with fluorescein was achieved. It also reduced DED symptoms and had a very good safety profile.</p><p><strong>Conclusions: </strong>the study formulation produced a significant improvement in the signs, symptoms, and QoL of patients with mild to moderate DED with a good safety profile after 1 month of treatment.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2559-2573"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141767005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Potential of Code-Free Custom GPTs in Ophthalmology: An Early Analysis of GPT Store and User-Creator Guidance. 探索无代码定制 GPT 在眼科领域的应用潜力:GPT 存储和用户创建指南的早期分析。
IF 2.6 3区 医学
Ophthalmology and Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1007/s40123-024-01014-w
Aslan Aykut, Almila Sarigul Sezenoz
{"title":"Exploring the Potential of Code-Free Custom GPTs in Ophthalmology: An Early Analysis of GPT Store and User-Creator Guidance.","authors":"Aslan Aykut, Almila Sarigul Sezenoz","doi":"10.1007/s40123-024-01014-w","DOIUrl":"10.1007/s40123-024-01014-w","url":null,"abstract":"<p><strong>Introduction: </strong>OpenAI recently introduced the ability to create custom generative pre-trained transformers (cGPTs) using text-based instruction and/or external documents using retrieval-augmented generation (RAG) architecture without coding knowledge. This study aimed to analyze the features of ophthalmology-related cGPTs and explore their potential utilities.</p><p><strong>Methods: </strong>Data collection took place on January 20 and 21, 2024, and custom GPTs were found by entering ophthalmology keywords into the \"Explore GPTS\" section of the website. General and specific features of cGPTs were recorded, such as knowledge other than GPT-4 training data. The instruction and description sections were analyzed for compatibility using the Likert scale. We analyzed two custom GPTs with the highest Likert score in detail. We attempted to create a convincingly presented yet potentially harmful cGPT to test safety features.</p><p><strong>Results: </strong>We analyzed 22 ophthalmic cGPTs, of which 55% were for general use and the most common subspecialty was glaucoma (18%). Over half (55%) contained knowledge other than GPT-4 training data. The representation of the instructions through the description was between \"Moderately representative\" and \"Very representative\" with a median Likert score of 3.5 (IQR 3.0-4.0). The instruction word count was significantly associated with Likert scores (P = 0.03). Tested cGPTs demonstrated potential for specific conversational tone, information, retrieval and combining knowledge from an uploaded source. With these safety settings, creating a malicious GPT was possible.</p><p><strong>Conclusions: </strong>This is the first study to our knowledge to examine the GPT store for a medical field. Our findings suggest that these cGPTs can be immediately implemented in practice and may offer more targeted and effective solutions compared to the standard GPT-4. However, further research is necessary to evaluate their capabilities and limitations comprehensively. The safety features currently appear to be rather limited. It may be helpful for the user to review the instruction section before using a cGPT.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2697-2713"},"PeriodicalIF":2.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progressive Thickening of Retinal Nerve Fiber and Ganglion Cell Complex Layers Following SDM Laser Vision Protection Therapy in Open-Angle Glaucoma 开角型青光眼患者接受 SDM 激光视力保护疗法后视网膜神经纤维和神经节细胞复合层逐渐增厚
IF 3.3 3区 医学
Ophthalmology and Therapy Pub Date : 2024-09-19 DOI: 10.1007/s40123-024-01029-3
Jeffrey K. Luttrull, Radouil Tzekov, Sathy V. Bhavan
{"title":"Progressive Thickening of Retinal Nerve Fiber and Ganglion Cell Complex Layers Following SDM Laser Vision Protection Therapy in Open-Angle Glaucoma","authors":"Jeffrey K. Luttrull, Radouil Tzekov, Sathy V. Bhavan","doi":"10.1007/s40123-024-01029-3","DOIUrl":"https://doi.org/10.1007/s40123-024-01029-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>This work aims to determine the effect on nerve fiber layer (NFL) and ganglion cell complex (GCC) thickness trends in eyes with open-angle glaucoma (OAG) treated with Vision Protection Therapy™ (VPT).</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A retrospective analysis of spectral-domain optical coherence tomography (OCT) measured NFL and GCC thickness trends was performed, excluding eyes with poor-quality scans and principal diagnoses other than OAG. This study compares eyes with OAG managed conventionally with IOP control alone (controls) to eyes managed with the addition of VPT (VPT eyes). The direction (+ or −) and magnitude (microns/year) of the OCT trends were the study endpoints.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Seventy-eight control eyes of 40 patients and 61 VPT-treated eyes of 39 patients were included in the study. Positive NFL trends were noted in 5% of control eyes vs. 71% of VPT eyes (<i>p</i> &lt; 0.0001). Positive GCC trends were noted in 8% of control eyes vs. 43% of VPT eyes (<i>p</i> &lt; 0.0001). Mean NFL trends (µm/year) were − 0.692 for controls vs. 0.347 for VPT (<i>p</i> &lt; 0.0001). Mean GCC trends (µm/year) were − 0.554 for controls vs. − 0.148 for VPT (<i>p</i> = 0.0175).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The addition of VPT to the conventional management of OAG resulted in highly significant improvements in NFL and GCC trends, indicating a reversal of key indicators of glaucoma severity and progression.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"39 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Influencing Treatment Preference in Patients with Diabetic Macular Edema: A Study Using Conjoint Analysis 影响糖尿病黄斑水肿患者治疗偏好的因素:联合分析法研究
IF 3.3 3区 医学
Ophthalmology and Therapy Pub Date : 2024-09-17 DOI: 10.1007/s40123-024-01026-6
Takao Hirano, Koji Tanabe, Toshinori Murata
{"title":"Factors Influencing Treatment Preference in Patients with Diabetic Macular Edema: A Study Using Conjoint Analysis","authors":"Takao Hirano, Koji Tanabe, Toshinori Murata","doi":"10.1007/s40123-024-01026-6","DOIUrl":"https://doi.org/10.1007/s40123-024-01026-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Despite the wide range of treatment options available for diabetic macular edema (DME), adherence to treatment remains a barrier. Therefore, this study used conjoint analysis to examine the factors that patients with DME prioritize when choosing a course of treatment and investigated differences in quality of life and levels of disease self-management in patients with or without experience of anti-vascular endothelial growth factor (VEGF) treatment.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A cross-sectional study was conducted through an online survey in Japan between May 31, 2022, and June 30, 2022. Questionnaires were sent to 27,236 individuals registered in the diabetes panels, with experience of treatment for DME within the last 10 years. Conjoint analysis was employed to calculate the relative importance, i.e., degree of influence on patients' treatment choices, considering the trade-offs among five factors: cost per treatment, frequency of visits, anticipated post-treatment visual acuity, physician’s explanation about disease and treatment, and frequency of treatment-related side effects.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 237 responses were used to assess the relative importance of cost per treatment, frequency of visits, anticipated post-treatment visual acuity, physician’s explanation about the disease, treatment, and frequency of treatment-related side effects using conjoint analysis. The importance of each factor was anticipated post-treatment visual acuity at 30.0, frequency of treatment-related side effects at 25.5, treatment frequency at 17.7, cost per treatment at 16.5, and physician explanation about the disease and treatment at 10.4. The average EuroQoL 5 dimension 5 level index value in patients with and without anti-VEGF treatment experience was 0.785 and 0.825, respectively, with no major difference.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Anticipated post-treatment visual acuity was identified as the most important factor in selecting a treatment regardless of the anti-vascular endothelial growth factor treatment experience demonstrating when patients with DME make treatment choices, anticipated post-treatment visual acuity is prioritized over treatment frequency and cost.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"55 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The I-OPTA Questionnaire: A National Assessment of Patients with Neovascular Age-Related Macular Degeneration I-OPTA 问卷:对新生血管性老年黄斑变性患者进行全国性评估
IF 3.3 3区 医学
Ophthalmology and Therapy Pub Date : 2024-09-16 DOI: 10.1007/s40123-024-01028-4
Benjamin Sommer Thinggaard, Kasper Hansen, Freja Dinesen, Maria Kjøller Pedersen, Lars Morsø, Yousif Subhi, Jakob Grauslund, Lonny Stokholm
{"title":"The I-OPTA Questionnaire: A National Assessment of Patients with Neovascular Age-Related Macular Degeneration","authors":"Benjamin Sommer Thinggaard, Kasper Hansen, Freja Dinesen, Maria Kjøller Pedersen, Lars Morsø, Yousif Subhi, Jakob Grauslund, Lonny Stokholm","doi":"10.1007/s40123-024-01028-4","DOIUrl":"https://doi.org/10.1007/s40123-024-01028-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Introduction</h3><p>Neovascular age-related macular degeneration (nAMD) is the leading cause of irreversible vision loss in developed countries. However, a significant gap persists in understanding this population, exacerbated by their advanced age and visual impairments, which can hinder research participation and access to healthcare. The purpose of this study was to describe the content of the questionnaire and the participating patients with nAMD.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The survey includes patients diagnosed with nAMD who had previously received treatment or were currently undergoing intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Participants were recruited using various methods, as reaching out to patients who are no longer receiving treatment poses a particular challenge. A patient and public advisory board assisted throughout the study period.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Of the 713 electronic invitations sent out, 494 (69.3%) patients responded to the questionnaire, with an additional 57 responses obtained through e-mail or telephone interviews. Due to the exclusion of 16 responses, there were a total of 535 valid responses, including 176 from patients previously treated and 359 from those currently undergoing treatment for nAMD. The median age of respondents was 79.9 years (interquartile range [IQR] 75.5–84.7), with 59.8% being women. Among them, 53.2% were married, while 43.1% lived alone.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Data from the I-OPTA (Identification of Patient-Reported Barriers in Treatment for nAMD) questionnaire allows future exploration of patients who are no longer receiving treatment, patients’ knowledge about preventive measures, and the impact of nAMD on visual function and quality of life. Future research, including studies that integrate data from corresponding retinal images and Danish national registers, has the potential to generate invaluable knowledge, providing benefits to both patients and healthcare professionals.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"215 1","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信